Compare Dow Jones Industrial Average ETF (DIA) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Jones Industrial Average ETF vs Novavax Inc — how do they compare? Dow Jones Industrial Average ETF trades at $516.7 (market cap $45.20B), while Novavax Inc trades at $12.97 (market cap $1.82B). The key difference: Dow Jones Industrial Average ETF is far larger — about 24.8× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Dow Jones Industrial Average ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dow Jones Industrial Average ETF for 104 Days and Novavax Inc for 59 Days on average.
| DIA | NVAX | |
|---|---|---|
Market Cap | $45.20B | $1.82B |
Volume | 4,095,368 | 6,198,505 |
52-Week High | $542.79 | $12.56 |
52-Week Low | $451.37 | $6.22 |
Typical Hold Time | 104 Days | 59 Days |
Sector | — | Health |
Enterprise Value | — | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DIA (SPDR Dow Jones Industrial Average ETF Trust) trades at $515.82, up 0.94% with bearish technical signals from moving averages. The ETF shows neutral oscillator readings with RSI at 46.24, while recent dividend distributions provide income appeal. Support levels cluster around $507-510 with resistance at $513-516.
Market sentiment reflects cautious optimism amid economic uncertainty, with institutional focus on Fed policy and earnings resilience. Key risks include interest rate sensitivity and market volatility, though the ETF's diversified Dow Jones exposure offers defensive characteristics in turbulent markets.
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
